Pyzchiva (ustekinumab-ttwe) is the third ustekinumab biosimilar to receive approval for the American market. It was also approved with interchangeability.
The FDA has approved Samsung Bioepis’ Pyzchiva (ustekinumab-ttwe) for the treatment of inflammatory conditions, including plaque psoriasis and ulcerative colitis.
The approval of Pyzchiva marks the third ustekinumab approval for the US as well as the 14th interchangeable biosimilar. | Image credit: Argus - stock.adobe.com
Pyzchiva marks the third biosimilar referencing Stelara (ustekinumab) to be approved for the American market, and the biosimilar was approved with an interchangeability designation, allowing for it to be substituted for the reference product at the pharmacy level without waiting for physician approval.
Upon launch, Pyzchiva will be available with intravenous and subcutaneous administration options. Here is the full list of patient indications:
“The FDA approval of Pyzchiva as a biosimilar to Stelara is an important milestone for patients living with inflammatory conditions, as biosimilars can offer more choice and access to biologic treatments,” said Byoung In Jung, vice president and regulatory affairs team leader at Samsung Bioepis. “In addition, biosimilars have a potential to reduce the financial burden of health care systems, especially in the US where biologics account for more than 46% of the annual drug spending. We will continue to reinforce our commitment to widen access to medicines by advancing our biosimilar pipeline for the benefits of patients, health care providers, and health care systems around the world.”
Psychiva’s approval follows those for Wezlana (ustekinumab-auub) in November 2023 and Selarsdi (ustekinumab-aekn) in April 2024. Wezlana was developed by Amgen and Selarsdi was developed by Alvotech and will be marketed in the US by Teva Pharmaceuticals as part of a commercialization partnership.
The FDA approved Pyzchiva based on comprehensive evidence, including analytical, nonclinical, and clinical data, confirming its biosimilarity to Stelara with no significant differences in safety, purity, or potency. A phase 1 study (NCT04772274) showed equivalent pharmacokinetics, safety, tolerability, and immunogenicity between Pyzchiva (SB17) and Stelara in healthy volunteers. A phase 3 study (NCT04967508) in patients with moderate to severe plaque psoriasis demonstrated similar efficacy, safety, and pharmacokinetics for SB17 and Stelara up to week 28. These findings were published in the Journal of the American Academy of Dermatology and presented at the 2024 American Academy of Dermatology annual meeting.
Pyzchiva, developed by Samsung Bioepis, will be commercialized by Sandoz in the US as part of a September 2023 commercialization agreement between the companies. Sandoz will have exclusive commercialization rights to Pyschiva in the US, Canada, European Economic Area, Switzerland, and the UK.
In the US, the license period for Pyzchiva will commence on February 22, 2025, as per the settlement and license agreement between Samsung Bioepis and Janssen Biotech, the maker of Stelara. Similar settlement agreements have resulted in delayed launches for Wezlana and Selarsdi from 2024 to 2025.
Samsung Bioepis has a portfolio of 11 biosimilars spanning immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. As of June 2024, 7 of these biosimilars are approved in the US, with 4 already commercially available.
Reference
FDA approves Pyzchiva (ustekinumab-ttwe), Samsung Bioepis’ biosimilar to Stelara. News release. Samsung Bioepis. July 1, 2024. Accessed July 1, 2024. https://www.biospace.com/article/releases/fda-approves-pyzchiva-ustekinumab-ttwe-samsung-bioepis-biosimilar-to-stelara/
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.